Hetero has a nod to sell covid drugs

The Controller General of Indian Drugs (CGDI) has authorized generic manufacturer Hetero to manufacture and market the investigational antiviral drug Remdesivir for the treatment of Covida-19.

The generic version of Remdesivir of Hetero is sold in India under the brand name COVIFOR.

With the increasing number of Covid-19 cases in India, the approval of COVIFOR (Remdesivir) could be a turning point given the positive clinical results, said Dr. B. Partha Saradhi Reddy, president of the Hetero Group.

Because we can rely on strong upstream integration, we can guarantee that the product is immediately available to patients across the country. We are prepared to supply enough stock to meet current needs, he said.

The product is manufactured in India in line with the do-it-yourself campaign. Remesevir has been approved by DCGI for the treatment of suspected or laboratory confirmed cases of Covid-19 in hospitalized adults and children with severe symptoms. COVIFOR (Remdesivir) will be available in a 100 mg vial (injection) for intravenous injection in a hospital under medical supervision.

The product is manufactured under a license agreement with Gilead Sciences Inc. to improve access to the Kovid 19 treatment in low and middle income countries.

On Sunday, the total number of Kovid-19 cases was 4,11621, with a record of 1,6021 cases in the last 24 hours. The ticket price reached 13269.

However, the number of patients recovering from Kovid-19 in India continues to increase. So far, 2,27,755 patients have been treated. In the past 24 hours a total of 13,925 Kovid 19 patients have been cured, with a healing rate of 55.49% among the Kovid 19 patients.

View the full image

Graphs : Pepermunthof

Several countries have introduced deterrence strategies. The efforts of the Government of Maharashtra and the Corporation of the Municipality of Brihanmumba (BMK) have yielded encouraging results in their efforts to torment the virus and have led to aggressive and targeted prosecutions in Dharavi, Mumbai.

In densely populated Dharavi (2,27,136 inhabitants/km2) there were 491 cases in April 2020, an increase of 12% and a doubling of the 18-day period. As a result of proactive measures taken by BMS, growth of Kovid-19 was reduced to 4.3% in May 2020 and to 1.02% in June. These measures also doubled the processing time of cases to 43 days in May 2020 and 78 days in June 2020.

There are currently 1,69,451 active cases in India, all under active medical surveillance. Today the number of cured patients has exceeded the number of active patients by 58,305, according to the Ministry of Health.

As part of a concerted action to develop laboratory and testing infrastructure, the number of public laboratories was increased to 722 and the number of private laboratories to 259 (981 in total).

The number of samples examined daily also continues to increase. 1,90,730 samples have been tested in the last 24 hours. The total number of samples tested so far is 68 07 226.

Sign up for the newsletter.

* Enter a valid email address

* Thank you for subscribing to our newsletter.